The timing of serum infliximab loss, or the appearance of antibodies to infliximab (ATI), is related with the clinical activity in ATI-positive patients with rheumatoid arthritis treated with infliximab

被引：7
|
作者：
Plasencia, Ch [1 ]
Pascual-Salcedo, D. [2 ]
Alcocer, P. [1 ]
Bonilla, M. G. [1 ]
Villalba, A. [1 ]
Peiteado, D. [1 ]
Arribas, F. [2 ]
Diez, J. [3 ]
Lopez-Casla, M. T. [2 ]
Martin-Mola, E. [1 ]
Balsa, A. [1 ]
机构：
[1] Paz Univ Hosp Idipaz, Dept Rheumatol, Paseo Castellana 261, Madrid 28046, Spain
[2] Paz Univ Hosp Idipaz, Immunol Unit, Madrid, Spain
[3] Paz Univ Hosp Idipaz, Stat Dept, Madrid, Spain
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷 / 11期
关键词：
Anti-TNF; Rheumatoid Arthritis; Treatment; IMMUNOGENICITY;
D O I：
10.1136/annrheumdis-2013-203353
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1888 / 1890
页数：3
相关论文
共 50 条
  • [21] Relationship between serum levels of infliximab, C-reactive protein and clinical response to infliximab in patients with rheumatoid arthritis
    Wolbink, GJ
    De Groot, E
    Lems, WF
    Nurmohamed, MT
    Tak, PP
    Dijkmans, BAC
    Aarden, L
    Voskuyl, AE
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 98 - 99
  • [22] Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission
    Nawata, Masao
    Saito, Kazuyoshi
    Nakayamada, Shingo
    Tanaka, Yoshiya
    MODERN RHEUMATOLOGY, 2008, 18 (05) : 460 - 464
  • [23] Clinical significance of occurrence of autoantibodies in rheumatoid arthritis patients treated with infliximab and methotrexate
    Novak, S
    Anic, B
    Cikes, N
    Sentic, M
    Bosnic, D
    Budiselic, R
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 386 - 386
  • [24] Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response
    Haraoui, B
    Cameron, L
    Ouellet, M
    White, B
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (01) : 31 - 36
  • [25] Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice
    Neven, N
    Vis, M
    Voskuyl, AE
    Wolbink, GJ
    Nurmohamed, MT
    Dijkmans, BAC
    Lems, WF
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (04) : 645 - 646
  • [26] Renal function in rheumatoid arthritis patients treated with methotrexate and infliximab
    Wiland, P
    Wiela-Hojenska, A
    Glowska, A
    Chlebicki, A
    Hurkacz, M
    Orzechowska-Juzwenko, K
    Szechinski, J
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2004, 22 (04) : 469 - 472
  • [27] Study of complement system in rheumatoid arthritis patients treated with infliximab
    Marchi, Larissa Favaro
    Paoliello Paschoalato, Adriana Balbina
    Landi Librandi, Ana Paula
    Caleiro Seixas Azzolini, Ana Elisa
    Marzocchi Machado, Cleni Mara
    Donadi, Eduardo Antonio
    Lucisano Valim, Yara Maria
    MOLECULAR IMMUNOLOGY, 2014, 61 (02) : 248 - 249
  • [28] Renal function in rheumatoid arthritis patients treated with methotrexate and infliximab
    Wiland, P
    Wiela-Hojenska, A
    Glowska, A
    Chlebicki, A
    Hurkacz, M
    Orzechowska-Juzwenko, K
    Szechinski, J
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 177 - 177
  • [29] Quality of life response in rheumatoid arthritis patients treated with infliximab
    Novik, AA
    Mesenova, T
    Ionova, TI
    Boitcov, SA
    Kishtovich, A
    Fedorenko, DA
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 473 - 473
  • [30] Bone mineral density in patients with rheumatoid arthritis treated with infliximab
    Vis, M
    Voskuyl, AE
    Wolbink, GJ
    Dijkmans, BAC
    Lems, WF
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (02) : 336 - 337
12345